(Reuters) -Shares in European vaccine makers fell on Friday after U.S. President-elect Donald Trump picked Robert F. Kennedy ...

Pharmaceutical companies are typically rewarded for their innovation with years of market exclusivity before cheaper generics ...

The excitement around the new weight-loss industry is overtaking other disease areas and portfolios for publicly traded ...

The stocks of companies that make or are developing the new class of weight-loss and diabetes-management drugs were sharply lower Friday, after President-elect Donald Trump named Robert F. Kennedy Jr.

About 400 people marched to the South African headquarters of Novo Nordisk A/S in Johannesburg this week demanding greater ...

Health stocks slumped on Friday as Wall Street weighed the impact that prominent vaccine skeptic Robert F. Kennedy Jr. could ...

Kennedy has been criticized for making false medical claims. He has also vowed to purge the U.S. Food and Drug Administration ...

Some school districts, including MSCS, have what's called a self-funded health plan. That means the employer pays for ...

The District 60 Board of Education unanimously approved a resolution hiring the Frantz Law Group Tuesday at the Lincoln Center administration building in Waukegan to help it recoup some of the ...

Vaccine stocks have struggled since RFK Jr.'s appointment to health secretary, with Moderna and Pfizer seeing the deepest ...

Shares in major pharmaceutical companies are down as well: Pfizer has fallen 4.6 percent, Eli Lilly 4.2 percent, Amgen 4.9 ...

When the healthcare sector sneezes, European investors catch a cold. That's what happened Friday after vaccine-skeptic Robert F. Kennedy Jr. was chosen for health and human services secretary.